跳至主要内容
临床试验/IRCT201112048299N1
IRCT201112048299N1已完成2 期

Clinical trial of oral magnesium oxide supplementation in prevention of cisplatin-induced hypomagnesaemia in cancer patients in Rasoul Akram hospital of Tehran university of medical sciences

Oncopathology Research Center of Tehran University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • cancer diagnosis, beginning chemotherapy with Cisplatin drug, absence of renal disease and alcoholism, leukemia, non-consumption of drugs such as diuretics, aminoglycosides, cyclosporine and amphotericin B
  • Exclusion criteria: death before end of treatment

排除标准

  • 未提供

研究者

发起方
Oncopathology Research Center of Tehran University of Medical Sciences

相似试验